CRISPR Therapeutics is poised for a significant year in 2025, building on the successful launch of CASGEVY, which has seen strong global demand and payer support. With a robust pipeline and approximately $1.9 billion in cash, the company plans to advance key candidates in oncology, autoimmune, and cardiovascular diseases, while continuing to innovate in gene editing technologies. The recent regulatory approval of CASGEVY in the UAE highlights its transformative potential for treating sickle cell disease and beta thalassemia.